On February 18, 2016, 22nd Century Group, Inc. (NYSE MKT: XXII) filed its Form 10K annual report for the year ending December 31, 2015. Early this morning the company held a conference call to provide an update for shareholders. Given that the company’s two key cigarette brands, MAGIC® and RED SUN®, are still in the early stages…
On Monday, February 8, 2016, at the BioCEO conference, Immune Pharmaceuticals Inc. (IMNP) made available a new investor presentation for shareholders that lays out the company’s key goals for 2016. Despite the precipitous decline in biotech stocks over the past three months, which no doubt has hit shares of Immune disproportionately hard, management remains aggressive in…
One of the most advanced clinical-stage candidates at RedHill Biopharma Ltd (RDHL) is RHB-105, a new triple combination therapy for the eradication of H. pylori infection in humans. RedHill has successfully completed a Phase 3 clinical trial with RHB-105, reporting positive results in June 2015 from the ERADICATE-Hp study. ERADICATE-Hp was a randomized, double-blind, placebo-controlled…
How Nuvo Research Splitting Into Two Companies Is A Win-Win For Shareholders Last week, Nuvo Research Inc. (NRI.TO) mailed a Management Information Circular to shareholders explaining the impetus and logistics for the planned separation of the company into two separately traded entities, a specialty pharmaceutical business to be called Nuvo Pharmaceuticals Inc., and a drug development…
Earlier in January, I alerted investors to the fact that 22nd Century Group (NYSEMTK: XXII) filed an MRTP application to the U.S. FDA for Brand-A, a code name for the company’s modified risk very low nicotine (VLN) cigarette that contains roughly 95% less nicotine per cigarette versus commercially available brands. MRTP stands for Modified Risk Tobacco Product,…
Last week in San Francisco, I had a good talk with Joseph P. Wagner, PhD, the CEO of BriaCell Therapeutics (BCT.V / BCTXF). He provide a good update on the current situation, which I report to investors in this article. Right now, the company’s is in active preparation to begin the Phase 2 trial, with…
Several months ago I wrote an article highlighting RedHill Biopharma’s (NASDAQ: RDHL) RHB-104, a patent-protected combination of clarithromycin, clofazimine, and rifabutin in a single oral pill, currently in Phase 3 trials for the treatment of Crohn’s disease (CD). I encourage investors to view that article >> HERE << because it provides a very good background on RHB-104…
Shares of Actinium Pharmaceuticals (ATNM) have moved significantly higher over the past month as investors are starting to come to grips with the potential for the company’s two pipeline products, Iomab-B and Actimab-A, both under investigation for the treatment of acute myeloid leukemia (AML). Iomab-B and Actimab-A are specific anti-cancer monoclonal antibodies (mAb) conjugated to alpha…
Last month I wrote a detailed article introducing investors to 22nd Century Group, Inc. (NYSEMKT:XXII), a Clarence, NY-based biopharmaceutical company founded in 1998 with proprietary technology in nicotine biosynthesis and tobacco plant-biotechnology. The company is engaged in the development and commercialization of tobacco harm reduction cigarettes and smoking cessation products, as well as the contract…
Last week, Gilead Sciences entered into a global partnership for the development and commercialization of filgotinib, a JAK1-selective inhibitor for inflammatory conditions, with Galapagos NV. Galapagos will receive an upfront payment of $725 million consisting of a cash license fee of $300 million and a $425 million equity investment. In addition, Galapagos is eligible for payments up to $1.35…